Press Releases

The life science group Sartorius and U.S.-based startup TheWell Bioscience have agreed to partner on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows. In addition to this, Sartorius will expand the portfolio of its lab division by distributing TheWell Bioscience's products and invest in a minority shareholding in the company. TheWell Bioscience is a pioneer in the field of animal-free hydrogels and bioinks,

Osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today an oral and poster presentation at the world´s leading clinical conference on bone, joint and muscle health (WCO-IOF-ESCEO) taking place in London from April 11-14, 2024 highlighting new clinical data from over 2.400 OsteoTest routine samples.

Today Toxys announces the peer-reviewed publication of the positive results from an international interlaboratory validation of ToxTracker©. ToxTracker is an in vitro method that accurately predicts genotoxicity without the use of animals. The results constitute an essential part of the approval process by the OECD for international acceptance of novel methods by regulatory authorities. The evaluation was finalized earlier in the year and data have been submitted to the OECD showing that

Celonic has signed a commercial license agreement with Revvity for its CHOSOURCE™ expression platform and TnT transposon technology. The Revvity expression platform will be used in combination with Celonic’s expertise and workflows to enhance the cell line development of monoclonal antibodies (mAbs) and complex proteins.   GS-CHOvolution® is based on Revvity’s gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO-K1) cGMP-

Evaxion Biotech A/S, hereinafter “Evaxion” or the “Company”, a clinical research-focused biotechnology company specializing in the development powerful vaccines based on its AI immunology platform, AI-Immunology™, is pleased to announce the successful completion of a series of large-scale studies investigating infections in non-rodent animals and targeting to test the antigens of EVX-B1, Evaxion's preclinical vaccine candidate against Staphylococcus aureus (S

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2024) brings together esteemed regionals partners with the mission to transform the industry with the green innovative solutions and cutting-edge technologies. The Congress takes place in Amsterdam, the Netherlands, on 22-23 April. This year, BGS Group welcomes the regional partners of PHARMAP 2024 to support the Congress and share commitment to a sustainable fut

Cardio Diagnostics Holdings, Inc, an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care navigation, wellness, and chronic care management offering. This collaboration aims to significantly expand access to Cardio Diagnostics' industry-le

DSM-Firmenich has announced a new strategic collaboration with Oz Medicann Group OMG Pharma – an Australian-based biotech innovator in the cannabinoid medicines domain – to explore the therapeutic potential of cannabidiol (CBD)-based orally dispersible tablets addressing insomnia. Leveraging dsm-firmenich’s high-quality GMP CBD active pharmaceutical ingredient (API) and leading-edge formulation capabilities, chiefly its bioavailability expertise, the wide-ranging collab

Revolutionary genomic research by Genzeva, LumaGene, RYLTI, Brigham & Women’s Hospital of Harvard University, and QIAGEN Digital Insights  applied an innovative use of multiomics and biomimetic digital twins to unveil new DNA variants associated with the development of endometrial related disorders. This study marks a significant leap forward in understanding the molecular mechanisms of endometrial-related disorders. In a paper published this week in the Journal of Mo

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose escalation part of a Phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer (“NSCLC”) that cannot be treated by surgery (“inoperable&